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IMPORTANCE Although growing evidence points to highly indolent behavior of encapsulated
follicular variant of papillary thyroid carcinoma (EFVPTC), most patients with EFVPTC are
treated as having conventional thyroid cancer.
OBJECTIVE To evaluate clinical outcomes, refine diagnostic criteria, and develop a
nomenclature that appropriately reflects the biological and clinical characteristics of EFVPTC.
DESIGN, SETTING, AND PARTICIPANTS International, multidisciplinary, retrospective study of
patients with thyroid nodules diagnosed as EFVPTC, including 109 patients with noninvasive
EFVPTC observed for 10 to 26 years and 101 patients with invasive EFVPTC observed for 1 to
18 years. Review of digitized histologic slides collected at 13 sites in 5 countries by 24 thyroid
pathologists from 7 countries. A series of teleconferences and a face-to-face conference were
used to establish consensus diagnostic criteria and develop new nomenclature.
MAIN OUTCOMES ANDMEASURES Frequency of adverse outcomes, including death from
disease, distant or locoregional metastases, and structural or biochemical recurrence, in
patients with noninvasive and invasive EFVPTC diagnosed on the basis of a set of
reproducible histopathologic criteria.
RESULTS Consensus diagnostic criteria for EFVPTCwere developed by 24 thyroid
pathologists. All of the 109 patients with noninvasive EFVPTC (67 treated with only
lobectomy, none received radioactive iodine ablation) were alive with no evidence of disease
at final follow-up (median [range], 13 [10-26] years). An adverse event was seen in 12 of 101
(12%) of the cases of invasive EFVPTC, including 5 patients developing distant metastases, 2
of whom died of disease. Based on the outcome information for noninvasive EFVPTC, the
name “noninvasive follicular thyroid neoplasmwith papillary-like nuclear features” (NIFTP)
was adopted. A simplified diagnostic nuclear scoring schemewas developed and validated,
yielding a sensitivity of 98.6% (95% CI, 96.3%-99.4%), specificity of 90.1% (95% CI,
86.0%-93.1%), and overall classification accuracy of 94.3% (95% CI, 92.1%-96.0%) for
NIFTP.
CONCLUSIONS AND RELEVANCE Thyroid tumors currently diagnosed as noninvasive EFVPTC
have a very low risk of adverse outcome and should be termed NIFTP. This reclassification will
affect a large population of patients worldwide and result in a significant reduction in
psychological and clinical consequences associated with the diagnosis of cancer.
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T he increasing incidence of cancer worldwide is multi-factorial, attributable to population longevity, chang-ing environmental and lifestyle factors, and increased
surveillance. Thyroid cancer is a prime example forwhich in-
tensified surveillance has resulted in an increasing incidence
ofearly cancerswith indolentbehavior,1,2 aphenomenoncom-
monlydescribedascancer “overdiagnosis.”3The increasing in-
cidence is solely attributable to papillary thyroid carcinoma
(PTC), a tumor named for its papillary growth pattern, al-
though thedefiningdiagnostic criteria are actually thenuclear
features of neoplastic cells.4 Aside from the enhanced screen-
ing, another important factor contributing to this phenom-
enon is the increase in diagnosis of a variant of PTC known as
the follicular variant of PTC (FVPTC).5
The follicular variant of PTCwasbroadly recognized in the
mid-1970sasatumorcomposedofneoplasticfolliclesratherthan
papillae,butwith follicular cells showingnuclear featureschar-
acteristic of PTC.4 Twomain subtypes are known to occur: in-
filtrative(ornonencapsulated)andencapsulated.6(pp100-109)7En-
capsulatedFVPTC(EFVPTC)has increasedinincidencebyanes-
timated 2- to 3-fold over the past 2 to 3 decades andmakes up
10%to20%ofall thyroidcancerscurrentlydiagnosed inEurope
andNorth America (eTable 1 in the Supplement).5,8
Encapsulated FVPTC is a challenging and controversial di-
agnosis inthyroidglandpathology. Inthosetumors thathaveno
invasion, thediagnosisofcancer restsexclusivelyonfindingthe
characteristicnuclei, assessmentofwhich inmanycases is sub-
jectiveandevencontentious, leadingtoconsistentlyhighinterob-
servervariability.9-11 Furthermore, studiesover thepastdecade
have demonstrated that FVPTC overall,12 and particularly
EFVPTC,hasanindolentbehaviorandisgeneticallydistinctfrom
infiltrativetumors.7,13-17Yet,mostpatientswithEFVPTCcontinue
tobetreatedsimilarlytothosewithconventionalPTC.Asidefrom
the stigmaof a “cancer”diagnosis and themorbidityof aggres-
sive treatment for PTC, patients and health care professionals
havetocopewiththerapidly increasingcostsofcare forpatients
withthyroidcancer,whichwereestimatedtoexceed$1.6billion
in 2013 in theUnited States alone.18
Recognizing the problem of overdiagnosis and overtreat-
ment of indolent cancers in many organs, the National Can-
cer Institute convened in 2012 a conference to evaluate this
problem. Following the conference, a statement from a num-
ber of participants emphasized the need to revise terminol-
ogy, replacing the word “cancer” when data emerge to sup-
port a more indolent designation.19 The goal of the current
project was to assemble an international group of expert pa-
thologists and clinicians to reexamine the entity currently
knownasEFVPTC through a reviewof a set of caseswith long
follow-up to (1) establish standardized diagnostic criteria and
(2) identify terminology thatwould appropriately address the
biological and clinical characteristics of this lesion.
Methods
Working Group
TheEndocrinePathologySocietyworkinggroupincluded24ex-
perienced thyroidpathologists (representing7 countries and4
continents), 2endocrinologists, 1 surgeon,and1psychiatrist. In
addition, amolecular pathologist, a biostatistician, and a thy-
roidcancer survivor/patientadvocateparticipated in thestudy.
Study Cohorts
For this retrospective study, a total of 268 tumors diagnosed
as EFVPTC using current histologic criteria were contributed
byworking grouppathologists from13 institutions (eMethods
in the Supplement) for inclusion into 2 groups. Potential cases
for group 1 included noninvasive EFVPTC with no radioio-
dine (RAI) treatmentandat least 10yearsof follow-up (n = 138).
Potential cases for group2 includedEFVPTCwithvascular in-
vasion and/or tumor capsule invasion andat least 1 year of fol-
low-up (n = 130). Shorter follow-up for group 2 was accepted
so as not to miss distant spread or recurrence within the first
years followingdiagnosis. The codedslidesweredigitized into
whole-slide images using the Aperio platform and placed on
aserver accessible to theentiregroup (http://image.upmc.edu:
8080/NikiForov%20EFV%20Study/view.apml).Thestudywas
performedunder institutional reviewboard/ethics committee
approval at 11 institutions, with exemption at 2 institutions,
withawaiverof informedconsentbecause thestudywasbased
on retrospective analysis of existing materials.
Histologic Review and Discussions
Twenty-four working group pathologists independently re-
viewed the scanned slides andprovided their diagnoses in ac-
cordance with the existing criteria (eMethods in the Supple-
ment). The diagnoses were tabulated and the initial findings
were presented at the initiation of an 8-week series of weekly
teleconferences aimed at refining groups 1 and 2 and achiev-
ing consensus. At a face-to-face conference inBoston,Massa-
chusetts, onMarch 20 and 21, 2015, the findings of the study,
together with related molecular and clinical outcome infor-
mation, were discussed and the new nomenclature was es-
tablished by consensus (eMethods in the Supplement). A
nuclear scoring schemewas subsequentlydevelopedandvali-
dated as detailed in the eMethods in the Supplement.
Molecular Analysis
Molecular analysiswasperformedon37 cases initially submit-
tedfor inclusionintogroup1onwhichparaffinblockswereavail-
Key Points
Question Do clinical outcomes of noninvasive encapsulated
follicular variant of papillary thyroid carcinoma (EFVPTC) warrant
reclassification of this tumor as nonmalignant?
Findings This study evaluates cases of encapsulated follicular
variant of papillary thyroid carcinoma to establish consensus
diagnostic criteria and develop new nomenclature. Among 109
patients with noninvasive EFVPTC, most of whomwere treated
with lobectomy only and none with radioiodine, all were alive with
no evidence of disease at a median follow-up of 13 years.
Meaning Thyroid tumors currently diagnosed as noninvasive
EFVPTC have a very low risk of adverse outcome and should be
termed “noninvasive follicular thyroid neoplasms with
papillary-like nuclear features” (NIFTP).
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able, and on 26 new cases of EFVPTC used as a validation set
for the nuclear score selected from the files of the Department
ofPathology,UniversityofPittsburgh.Total nucleic acidswere
isolated fromformalin-fixedandparaffin-embeddedtumor tis-
sue followingmanualmicrodissection.Molecular analysiswas
performedusingThyroSeqv2panel aspreviouslydescribed.20
Theassayusestargetednext-generationsequencinganalysis for
detecting pointmutations and indels in 14 genes (AKT1, BRAF,
CTNNB1,GNAS,HRAS,KRAS,NRAS,PIK3CA,PTEN,RET,TP53,
TSHR, TERT, EIF1AX) and 42 gene fusion types involving the
RET, BRAF, NTRK1, NTRK3, ALK, PPARG, and THADA genes.
Samples that showed more than 5% of mutant alleles (corre-
sponding to 10%ofcellswithheterozygousmutation) forpoint
mutationsormore than 100high-quality reads crossing the fu-
sionpointof the transcriptwereconsideredpositive.Themini-
mumdepth of coverage for each gene was 500×.
Statistical Analysis
Data analyseswere divided into a training phase and testing or
validationphase. In the trainingphase,23pathologists,blinded
tomoleculardiagnosis,provideda3-pointnuclear score (range,
0-3per case) for eachof 13 cases.With themoleculardata serv-
ing as the reference standard, a random-effects logistic regres-
sionmodel was fitted to predict molecular diagnosis based on
molecularstatusandindividualpathologist’snuclearscore.The
logistic model accounted for correlation among pathologists
evaluating the same case. The predicted probability of calling
acasepositivewascomputedandthecutoffproviding themost
accuratedecisionwasascertained.Thismethoddetectedmini-
mal impact of individual pathologist, and therefore a simpli-
fied decision rule that ignored the individual pathologist was
also calculated. This simplified rule was selected for valida-
tion.Validationof the simplified rulewas tested ina secondco-
hort of 26 patients with molecular diagnoses. Once again, pa-
thologists (N = 22) blindly scored each case with a 3-point
nuclear score. Treating the 22 test pathologists as indepen-
dent and combining their evaluations, the decision rule from
the training phase was then summarized by computing sensi-
tivity, specificity, positive predictive value, and accuracy.
Results
Consensus Diagnostic Features of Encapsulated FVPTC
Reviewofrepresentativedigitalandstill imagesandsubsequent
discussions identified a list of major andminor diagnostic cri-
teriaforEFVPTCusedbythemajorityofthyroidpathologistspar-
ticipatinginthestudy(Box1,Figure1,andeFigure1intheSupple-
ment). Furthermore, as a result of the discussion, consensus
exclusioncriteria forEFVPTCwereaccepted (Box 1). The initial
review and rereview of cases in both groupswas conducted in
a blinded fashion, ie, without knowledge of follow-up.
Results of Initial andSubsequentReviewsofCases inGroup 1
The initial reviewof 138potential cases forgroup1 (noninvasive
EFVPTC) resulted in 105 (76%) cases having the diagnosis of
EFVPTC rendered by 12 ormore (≥50%) pathologists and only
1 casewithaconcordantdiagnosisof abenignnodule rendered
byall24pathologists.Overall, thedegreeofexpressionofnuclear
featuresofPTCcorrelatedwiththeproportionofpathologistsren-
dering thediagnosis of EFVPTC (eFigure 2 in the Supplement).
Following the acceptance of the aforementioned consen-
susdiagnostic criteria, 30cases fromgroup1with themostdis-
parate diagnoses rendered on the initial review were rere-
viewedanddiscussed at teleconferences. As a result, 28 cases
were excluded from group 1 because of insufficient diagnos-
ticnuclear featuresofPTC(n = 14),presenceof invasion (n = 6),
at least 1% papillary growth consistent with classical PTC
(n = 4), or prominent (>30%) solid/trabecular/insular growth
pattern consistent with either solid variant PTC or poorly dif-
ferentiated thyroid carcinoma (n = 4). One case was submit-
Box 1. Consensus Diagnostic Criteria for the Encapsulated
Follicular Variant of Papillary Thyroid Carcinoma (EFVPTC)
Major Features
Encapsulation or clear demarcation
Follicular growth pattern
Nuclear features of papillary thyroid carcinoma (PTC)a:
Enlargement, crowding/overlapping
Elongation
Irregular contours
Grooves
Pseudoinclusionsb
Chromatin clearingc
Minor Features
Dark colloid
Irregularly shaped follicles
Intratumoral fibrosis
“Sprinkling” signd
Follicles cleft from stromad
Multinucleated giant cells within follicles
Features Not Seen/Exclusion Criteria
“True” papillaee >1%
Psammoma bodies
Infiltrative border
Tumor necrosis
Highmitotic activityf
Cell/morphologic characteristics of other variants of PTCg
a In a tumor with multifocal presence of PTC, most pathologists do not
require a specific minimal percentage of the tumor nodule to demonstrate
these features.
b Amajor and helpful diagnostic feature for all variants of PTC, although
uncommon in EFVPTC.
c Effacement of normal chromatin distribution with margination of chromatin
to membrane also known as “glassy nuclei” or “Orphan Annie” nuclei.
d As described and illustrated by Vanzati et al.21
e True papillae are defined as complex, arborizing papillae with fibrovascular
cores, lined by cells with nuclear features of PTC, and not associated with a
fine-needle aspiration area.
f At least 3 per 10 high-power fields (×40).
g Such as tall cell features, cribriform-morular variant, solid variant, etc.
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ted and reviewed twice under different coded numbers; the
duplicatewas eliminated. This resulted in a total of 109 cases
accepted as noninvasive EFVPTC in group 1.
Results ofMutational Analysis of Selected Cases in Group 1
Mutationalanalysiswasperformedon37cases initially submit-
tedasgroup1.Theanalysisassessedpointmutations in14genes
and42typesofgenefusions,whichare foundin approximately
90%ofPTC.22Clonalmolecular alterationsweredetected in25
(68%) of cases, with RASmutations being the most common
(eTable2 in theSupplement).Noneof the5casesexcludedfrom
group 1 as a result of insufficient nuclear features had identifi-
ablemutations. In contrast, 21 (78%) of genetically character-
ized lesions remaining in group 1 revealed clonalmutations.
Results of Initial andSubsequentReviewsofCases inGroup2
A total of 130 cases were submitted as group 2, EFVPTC with
invasion. These tumors had the samenuclear features and fol-
liculararchitectureasgroup1but,unlikegroup1cases,hadvas-
cular and/or tumor capsule invasion. Initial reviewyielded 105
(81%) cases that were diagnosed as EFVPTC with invasion by
at least 50% of reviewers, whereas the remaining cases were
preferentially called either classic PTC or infiltrative FVPTC
(eTable3 in theSupplement).After reviewanddiscussionof44
caseswiththemostdiscrepantdiagnosesat teleconferencesand
application of the consensus diagnostic criteria, 29 caseswere
excludedfromgroup2onthebasisofat least1%papillarygrowth
(n = 17), infiltrative border (n = 8), lack of the nuclear features
of PTC (n = 3), or lack of invasion (n = 2). As a result, 101 cases
remained in group 2. This included 80 cases with invasion of
the tumor capsule, 12 with vascular invasion, and 9with both
invasion types (eFigure 3 in the Supplement).
Follow-up for Patients in Study Groups
At the face-to-face conference, the follow-up informationwas
provided, as summarized in the Table. In group 1, among 109
patients observed for 10 to 26years, allwere alivewithnoevi-
denceofdisease.Sixty-sevenof thesepatientsweretreatedwith
lobectomy only, and none of them received RAI. In group 2,
among 101 patients, 85 patients were treatedwith RAI, 15 did
not receive RAI, andRAI treatment status in 1 patientwas un-
known. Patients were observed for 1 to 18 years, and 12 (12%)
registeredanadverseevent.Of those, 5patientsdevelopeddis-
tantmetastases (lungand/or bone), 2ofwhomdiedofdisease.
In addition, 1 patient had a lymphnode recurrence, 1 had per-
sistent disease, and5haddetectable serumthyroglobulin and
were considered to have either an indeterminate response or
biochemically incomplete response to therapy (eTable4 in the
Supplement). Among 5 patients who had distant metastases,
at presentation2 tumorshadcapsular invasiononly, 1hadvas-
cular invasion only, and 2 had both types of invasion.
Revision of Tumor Nomenclature
Based on the outcome information available for tumors diag-
nosedusing standardized criteria, newnomenclaturewasde-
veloped. Thegoalwas tooffer a designation for the lesion cur-
Figure 1. Gross and Histopathologic Features of the Tumor Currently Known as Encapsulated Follicular Variant
of Papillary Thyroid Carcinoma (EFVPTC)
Tumor with thin capsuleA Encapsulation and microfollicular growth pattern
of the tumor
B
Nuclear enlargement and elongationC Irregular nuclear contours and chromatin clearingD
10 cm
N
N
T
T
A, Gross appearance of a tumor with
thin capsule. B, Encapsulation
(arrowhead) andmicrofollicular
growth pattern of the tumor (T) as
compared with adjacent normal
thyroid (N) (hematoxylin-eosin
[H&E], original magnification ×100).
C, Major diagnostic nuclear features
including nuclear enlargement and
elongation, which is best appreciated
when nuclear size and shape of the
tumor (T) is compared with that of
adjacent normal tissue (N) (H&E,
original magnification ×400). D,
Irregular nuclear contours and
chromatin clearing (H&E, original
magnification ×400). Nuclear
pseudoinclusions and nuclear
grooves, as well as minor diagnostic
criteria, are illustrated in eFigure 1 in
the Supplement.
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rently known as noninvasive EFVPTC that would reflect the
following characteristics:
1. mainmorphological features, ie, the follicular growth pat-
tern and nuclear features of PTC;
2. lack of invasion, which separates this tumor from invasive
EFVPTC;
3. clonalorigindeterminedbyfindingadrivermutation,which
indicates that the lesion is biologically a neoplasm; and
4. a very low risk of adverse outcomewhen the tumor is non-
invasive.
Additional considerationwas tousewords translatable to
other languages without losing their exact meaning. As a re-
sult, the term “noninvasive follicular thyroid neoplasm with
papillary-like nuclear features” (NIFTP) was accepted.
Diagnostic Nuclear Score
Toprovide simplified and reproducible criteria for thenuclear
features that could assist in the diagnosis of NIFTP in routine
pathologypractice, the6mainconsensusnuclear features (Box
1) were grouped into 3 categories: (1) size and shape (nuclear
enlargement/overlapping/crowding, elongation), (2) nuclear
membrane irregularities (irregular contours, grooves, pseudo-
inclusions), and (3) chromatin characteristics (clearing with
margination/glassy nuclei). A 3-point scoring schemewas de-
veloped, inwhich each class of nuclear featureswas assigned
a score of 0 or 1, yielding a range of scores from0 to 3. Using a
visual guide for scoring the nuclear features (eFigure 4 in the
Supplement), 30 cases from group 1were evaluated by 23 pa-
thologistswhowereblinded to the results ofmolecular analy-
sis availableon18of these lesions (eTable5 in theSupplement).
Usingamolecular endpoint as the reference standard separat-
ingNIFTPfrombenignhyperplasticnodules, thescoringscheme
delivered themost accurate classificationwhena score of0or
1wasdiagnostic of abenignnodule anda scoreof 2or 3wasdi-
agnosticofNIFTP.This approachdemonstrateda sensitivityof
86.5% (95% CI, 82.7%-90.3%), specificity of 80.8% (95% CI,
73.8%-87.9%), and overall accuracy of 85.0% (82.8%-90.3%).
The3-point scoring schemewas thenvalidated in an indepen-
dent set of 26 new cases withmolecular end points (eTable 6
in theSupplement).Usinga0 to 1vs2 to3 score separation, the
3-point scoring schemeshoweda sensitivityof98.6%(95%CI,
96.3%-99.4%), specificityof90.1%(95%CI,86.0%-93.1%), and
overall classificationaccuracyof94.3%(95%CI,92.1%-96.0%).
Finaldiagnosticcriteria forNIFTParesummarized inBox2.
Discussion
Thisstudywasundertakentoreexaminetheclinicalandpatho-
logic approach tononinvasiveEFVPTC—a thyroid tumor that,
despite increasing evidence of its indolent behavior, is none-
theless classified as cancer. Theoutcomedata obtained in this
study support renaming this tumor in amanner thatmore ac-
curately reflects its behavior. Indeed, inourhighly curated co-
hort ofmore than 100noninvasiveEFVPTCs therewereno re-
currences or other manifestations of the disease at a median
follow-upof 13 years. This finding correlateswithprevious re-
ports on noninvasive EFVPTC. In the English language litera-
ture, only 2 (0.6%) of 352 well-documented noninvasive en-
capsulated/well-circumscribedFVPTCs recurred.14,15,23-27One
of therecurredtumorshadbeen incompletelyexcised,whereas
in the other case the noninvasive nature of the tumor re-
mainsquestionable. Even if these 2 cases of recurrence are ac-
cepted, the combined data suggest that in the absence of in-
vasion this lesion entails a very low risk of adverse outcome
and therefore should not be termed cancer.
The new proposed terminology, NIFTP, reflects key histo-
pathologic features of this lesion, ie, lack of invasion, follicular
growth pattern, and nuclear features of PTC.Molecular analy-
sisperformed in this studyona limitednumberof samplescon-
firmed previous observations16,28 demonstrating that most of
these lesions are driven by clonal genetic alterations and are
therefore neoplasms rather than hyperplastic proliferations.
When defined with strict histopathologic criteria, these tu-
mors are not expected to show molecular alterations associ-
ated with classic PTC, such as BRAF V600E mutations. In-
stead, they demonstrate a high prevalence of RAS and other
mutations,whichhavebeen associatedwith follicular-pattern
thyroidtumors, includingfollicularadenoma(FA), follicular thy-
Table. Summaryof Follow-up Information for Patients in theStudyGroups
Characteristic
Group 1 (Noninvasive
EFVPTC)
(n = 109)
Group 2 (Invasive
EFVPTC)
(n = 101)
Age, mean (range), y 45.9 (21-81) 42.8 (8-78)
Sex, No. (%)
Female 91 (83) 71 (70)
Male 18 (17) 30 (30)
Tumor size, mean (range), cm 3.1 (1.1-9.0) 2.5 (0.6-5.5)
Extent of surgery
Lobectomy 67 15
Total thyroidectomy 42 86
Follow-up, y
Mean (range) 14.4 (10-26) 5.6 (1-18)
Median 13.0 3.5
Adverse events during follow-
up, No. (%)
0 12 (12)
Box 2. Diagnostic Criteria for NIFTP
1. Encapsulation or clear demarcationa
2. Follicular growth patternb with
<1% Papillae
No psammoma bodies
<30% Solid/trabecular/insular growth pattern
3. Nuclear score 2-3
4. No vascular or capsular invasionc
5. No tumor necrosis
6. No highmitotic activityd
a Thick, thin, or partial capsule or well circumscribed with a clear demarcation
from adjacent thyroid tissue.
b Includingmicrofollicular, normofollicular, or macrofollicular architecture
with abundant colloid.
c Requires adequate microscopic examination of the tumor capsule interface.
d Highmitotic activity defined as at least 3 mitoses per 10 high-power fields
(400×).
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roid carcinoma (FTC), and EFVPTC.16,22,29 Furthermore, tu-
mors analyzed in this study also recapitulate the FA to FTC se-
quence of progressionwith the capacity for invasion, suggest-
ing that NIFTP likely represents the “benign” counterpart or
precursor of the invasive EFVPTC (Figure 2).
Wehavedefinedasetofreproduciblediagnosticcriteria that
accurately identify NIFTP. We have also shown that given the
metastatic potential of the invasive tumors in group 2, ad-
equate sampling of the tumor capsule interface to exclude in-
vasion is imperative before designating a nodule as NIFTP. To
our knowledge, adequacy of tumor capsule sampling has not
beendiscussed in the literature to datewith respect to FVPTC.
Precedent can be drawn from the approach to the encapsu-
latedFA/FTCtumors, inwhichhistologic assessmentof theen-
tire lesional capsule is preferable to exclude aminimally inva-
sive FTC.30 Thus, like FA, NIFTP should undergo extensive
review of the tumor capsule interface to exclude invasion.
The resultsof this study, togetherwithpreviously reported
observations, suggest thatwhenthediagnosisofNIFTP ismade
onthebasisofcarefulhistopathologicalexamination, thetumor
willhavea lowrecurrencerate, likely less than1%withinthefirst
15years.Ofnote,mostdifferentiatedthyroidcarcinomasrelapse
withinthefirstdecadeafter initial therapy,31althoughlaterecur-
rencesanddistantspreadaredocumented.32 Importantly,a large
proportion of patients with tumors diagnosed as NIFTP in the
presentstudyunderwent lobectomyonlyandnonereceivedRAI
ablation.Thissuggeststhatclinicalmanagementofpatientswith
NIFTP can be deescalated because they are unlikely to benefit
from immediate completion thyroidectomy and RAI therapy.
Stagingwouldbeunnecessary. Inadditiontoeliminatingthepsy-
chological impactof thediagnosis of cancer, thiswould reduce
complicationsof total thyroidectomy, riskof secondary tumors
following RAI therapy, and the overall cost of health care.33,34
Avoidance of RAI treatment alonewould save between $5000
and$8500perpatient (basedonUScost).35Decreasedlong-term
surveillancewould account for another substantial proportion
of cost reduction.
Conclusions
The results of this international and multidisciplinary study
establish that thyroid lesions currently diagnosed as nonin-
vasiveEFVPTCrepresentadistinct classof thyroid tumorswith
very low risk of adverse outcome. These tumors can be diag-
nosedusingasetof reproduciblediagnostic criteria andshould
be termed“noninvasive follicular thyroidneoplasmswithpap-
illary-like nuclear features” (NIFTP).We estimate that this re-
classification would affect more than 45000 patients world-
wide each year (eTable 7 in the Supplement), thereby
significantly reducing thepsychological burden,medical over-
treatment and expense, and other clinical consequences as-
sociated with a cancer diagnosis.
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